Eko Low Ejection Fraction Tool (ELEFT) vs Us2.v1

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AI Verdict

Eko Low Ejection Fraction Tool (ELEFT) is designed for early detection of low ejection fraction during routine physical exams using digital stethoscopes, serving as a screening tool. In contrast, Us2.v1 provides fully automated, comprehensive analysis of echocardiography images for detailed diagnosis and reporting. Therefore, they address different stages of cardiac assessment, with ELEFT focusing on initial screening and Us2.v1 on in-depth diagnostic imaging analysis.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Frequently Asked Questions

How do these tools integrate into existing clinical workflows for cardiac assessment, and what is their primary clinical application?

Eko Low Ejection Fraction Tool (ELEFT) is designed for non-invasive screening during routine physical exams using a digital stethoscope to aid in the early detection of low ejection fraction. Us2.v1, conversely, automates the comprehensive analysis of echocardiograms, providing detailed reports for diagnostic purposes.

Beyond low ejection fraction, what other cardiac conditions can each tool help detect or analyze, and for which medical specialties are they primarily intended?

ELEFT focuses on aiding the early identification of low ejection fraction, a key indicator of heart failure, and is suitable for Cardiology, Family Medicine, and Internal Medicine. Us2.v1 offers comprehensive echocardiography analysis, including automated detection of cardiac amyloidosis and pulmonary hypertension, primarily for Cardiology.

Can you describe the output and reporting capabilities of each tool, and how quickly are results generated?

ELEFT analyzes ECG and heart sound recordings to provide low ejection fraction detection results in approximately 15 seconds. Us2.v1 generates comprehensive structured reports with measurements, disease detection, and findings in seconds, offering editable annotations and comparison to international reference guidelines.

What is the anticipated learning curve for physicians and staff, and how do these tools contribute to overall operational efficiency in a clinical setting?

Both tools emphasize rapid integration into workflows; ELEFT provides results in 15 seconds during a routine exam, while Us2.v1 offers 'zero-click' and real-time analysis in seconds. This focus on speed suggests a minimal learning curve and significant contributions to efficiency by automating aspects of cardiac assessment.

How do these tools facilitate integration with existing Electronic Health Record (EHR) systems for data transfer and reporting?

ELEFT integrates with Eko digital stethoscopes and is part of the SENSORAu2122 platform, with data processed and stored in the cloud, suggesting a pathway for data flow. Us2.v1 can deliver structured reports back to PACS, CVIS, or EMR systems, supporting HL7 and DICOM SR, and integrates via standard DICOM routing.

What is the accuracy or sensitivity of each tool in detecting the specified cardiac conditions?

ELEFT has demonstrated an AUROC of 0.85 for detection of LVEF below 40%, with 84.8% sensitivity and 69.5% specificity in an independent validation, and 74.7% sensitivity and 77.5% specificity in a multi-site clinical study. Us2.v1's fully automated measurements have been shown to be completely interchangeable with expert human measurements and reproducible for a given patient study.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

Backers

Who funded each tool's parent company.